The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
12 January 2024
Cellular Goods PLC
("Cellular Goods" or "The Company")
Director's Dealings
Cellular Goods (LSE: CBX), a UK-based company pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions, announces that Michael Edwards (Executive Director of Cellular Goods) has purchased a total of 1,400,000 ordinary shares in the Company ("Ordinary Shares"), the details of which are set out in the notification below. Following this purchase, Michael Edwards holds a total of 9,400,000 Ordinary Shares, representing 1.56 per cent of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Michael Edwards | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Executive Director | ||||
| b) | Initial notification / Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Cellular Goods PLC | ||||
| b) | LEI | 213800IXPX4Z2MKX2U28 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares | ||||
| | Identification Code | GB00BK964W87 | ||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price |
1,400,000 Ordinary Shares 0.707 pence per Ordinary Share | ||||
| e) | Date of the transaction | 11 January 2024 | ||||
| f) | Place of the Transaction | London Stock Exchange | ||||
For further information please contact:
| Cellular Goods | |
| Michael Edwards Director | via FSCF +44 7572 873 300 |
| First Sentinel Corporate Finance (FSCF) | |
| Investor Relations Rebecca Noonan Media Relations Rebecca Noonan Corporate Broker & Advisor Brian Stockbridge |
+44 7572 873 300
+44 7572 873 300
+44 7858 888 007 |
| Novum Securities |
|
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
About Cellular Goods PLC:
Cellular Goods is pioneering the use of lab-based and biosynthetic production methods for wellness and sustainability solutions. The Company launched with a focus on efficacy led and science-backed products utilising biosynthetics, and now employs its expertise across two verticals: premium next-generation cannabinoid skincare products, and carbon sequestration-as-a-service through its wholly owned business division, King Tide Carbon, which utilises biosynthetic algae and seaweed to provide scalable carbon removal. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.